Rapid Micro Biosystems, Inc（RPID）财务数据RPIDRapid Micro Biosystems, Inc

Rapid Micro Biosystems, Inc. (RPID) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 69.7% of total sales, equivalent to $5.58M. Another important revenue stream is Service revenue. Understanding this composition is critical for investors evaluating how RPID navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Rapid Micro Biosystems, Inc. maintains a gross margin of 15.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -152.99%, while the net margin is -160.45%. These profitability ratios, combined with a Return on Equity (ROE) of -141.65%, provide a clear picture of how effectively RPID converts its operational activities into shareholder value.

In the context of the broader market, RPID competes directly with industry leaders such as AIOS and DSWL. With a market capitalization of $31.82M, it holds a significant position in the sector. When comparing efficiency, RPID's gross margin of 15.05% stands against AIOS's 63.57% and DSWL's 23.44%. Such benchmarking helps identify whether Rapid Micro Biosystems, Inc. is trading at a premium or discount relative to its financial performance.

Rapid Micro Biosystems has shown fluctuating revenue with Q1 2026 revenue at $8 million, but it reported a widening net loss of $14.3 million, reflecting ongoing financial struggles. The gross margin improved to 15.05% in Q2 2026, but overall profitability remains a concern.